Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone versus N-acetylcysteine for prevention of post-embolization syndrome in hepatocellular carcinoma
TCTR20250607002Phase 3Completed
- Sponsor
- Office of Research and Development, Phramongkutklao Hospital and College of Medicine
- Start
- Jul 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dexamethasone, acetylcysteine in hepatocellular carcinoma (HCC), post-embolization syndrome (PES), sponsored by Office of Research and Development, Phramongkutklao Hospital and College of Medicine. Started Jul 2023; status: completed.
02
Drugs
dexamethasoneacetylcysteine
03
Conditions
hepatocellular carcinoma (HCC)post-embolization syndrome (PES)
Beyond the preview
Go deeper on TCTR20250607002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250607002.